IC
KLRS

Ikarian Capital’s Kalaris Therapeutics KLRS Stock Holding History

Ikarian Capital’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.47M Hold
360,000
– – 0.16% 98
2026
Q1 		$2.08M Hold
360,000
– – 0.17% 98
2025
Q4 		$3.04M Buy
+360,000
New +$2.3M 0.24% 85

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Ikarian Capital's KLRS Position: Q2 2026 in Review

Ikarian Capital held its Kalaris Therapeutics (KLRS) position steady in Q2 2026 at 360,000 shares worth $1.47M. The position accounts for 0.16% of the portfolio, ranked #98.

Ikarian Capital first reported a position in KLRS in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.04M in Q4 2025. 57 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • Ikarian Capital held 360,000 shares of Kalaris Therapeutics worth $1.47M as of Q2 2026.
  • Ikarian Capital left its Kalaris Therapeutics share count unchanged in Q2 2026.
  • Kalaris Therapeutics made up 0.16% of Ikarian Capital's portfolio in Q2 2026, its #98 holding.
  • Ikarian Capital first reported a position in Kalaris Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Ikarian Capital's Kalaris Therapeutics position peaked at $3.04M in Q4 2025.
  • 57 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.